Abstract
Glucokinase (GK) is a new target for the treatment of type II diabetes mellitus (T2DM). In order to find a structure-simplified small molecule GK activator, 19 salicylic acid derivatives were designed and synthesized based on new lead compound (1). Experimental results showed that the potency of compound 8h is superior to control RO-28-0450 in GK activation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Drug Design
-
Enzyme Activation / drug effects
-
Enzyme Activators / chemical synthesis*
-
Enzyme Activators / chemistry
-
Enzyme Activators / pharmacology
-
Glucokinase / metabolism*
-
Hypoglycemic Agents / chemical synthesis*
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / pharmacology
-
Molecular Structure
-
Salicylates / chemical synthesis*
-
Salicylates / chemistry
-
Salicylates / pharmacology
-
Thiazoles / pharmacology
Substances
-
Enzyme Activators
-
Hypoglycemic Agents
-
RO-28-0450
-
Salicylates
-
Thiazoles
-
Glucokinase